Brean Murray Carret Raises Price Target on Achillion Pharmaceuticals (ACHN) Due to ACH-1625 Clinical Profile
ACHN Hot Sheet
Rating Summary:10 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 82
Brean Murray Carret & Co. is reiterating its Buy rating on sharers of Achillion Pharmaceuticals (NASDAQ: ACHN) while raising its price target from $9 to $20 following an update of the company's pipeline.
The company announced a few clinical data sets from the company's pipeline. The firm believes ACHN is strongly positioned compared to its peers given the company's high EVR rate, excellent resistance profile, and genotype 3 activity.
An analyst at the firm comments, "We see this data as being indicative of a breakdown in the classical mechanistic paradigm associated with protease inhibitors (good potency, poor resistance, and genotypic coverage), just as Pharmasset's (Nasdaq: VRUS) data last demonstrated that nucleotides could also be potent."
Brean Murray Carret notes the price target increase is based on a "substantially" stronger than previously expected clinical profile for ACH-1625.
For FY12 and FY13, the firm is forecasting EPS of ($0.62) and ($0.65), slightly better than the Street's consensus of ($0.64) and ($0.68).
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $9.72 yesterday, with a 52 week range of $3.81-$9.86.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
The company announced a few clinical data sets from the company's pipeline. The firm believes ACHN is strongly positioned compared to its peers given the company's high EVR rate, excellent resistance profile, and genotype 3 activity.
An analyst at the firm comments, "We see this data as being indicative of a breakdown in the classical mechanistic paradigm associated with protease inhibitors (good potency, poor resistance, and genotypic coverage), just as Pharmasset's (Nasdaq: VRUS) data last demonstrated that nucleotides could also be potent."
Brean Murray Carret notes the price target increase is based on a "substantially" stronger than previously expected clinical profile for ACH-1625.
For FY12 and FY13, the firm is forecasting EPS of ($0.62) and ($0.65), slightly better than the Street's consensus of ($0.64) and ($0.68).
For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.
Shares of Achillion Pharmaceuticals closed at $9.72 yesterday, with a 52 week range of $3.81-$9.86.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- UBS Lowers Estimates and PT on Lowe's (LOW) Messy Q1, But Bullish Case Remains
- Canaccord Genuity maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Bumping Guidance on Testim Partnership with GSK
- Barclays Maintains an 'Overweight' on Tidewater (TDW); Dayrates Climb, But Adjusting Numbers Lower on Expenses
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Brean Murray Carret & Co.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
